CSL Limited Share Price: Aussie Biotech Giant Faces $17 Billion Hit as U.S. Vaccine Demand Falls
In recent weeks, the CSL share price has come under intense pressure as Australia’s biotech powerhouse confronts weakening U.S. vaccine demand, driving a dramatic shift in investor sentiment. Once regarded as a stable performer among healthcare stocks, CSL now faces a sharp reassessment of its growth prospects and strategic direction. What’s happening with the CSL…